Interv Akut Kardiol. 2016;15(1):37-40 | DOI: 10.36290/kar.2016.007

Percutaneous closure of atrial septal defects

Vladimír Karmazín, Michael Želízko, Bronislav Janek, Tomáš Marek, Petr Lupínek, Michal Brzák
Institut klinické a experimentální medicíny, Praha

In the present paper we summarize our experience with percutaneous closure of atrial septal defects with the Amplatzer septal

occluder. A group of our patients is presented who were examined during the last 15 years, that is, the whole period for which the

technique has been performed at our department. The group includes 399 patients: in 174 patients closure of ASD was performed,

in 255 patients it was closure of PFO. Some controversial issues, particularly concerning PFO defects, are analyzed. We conclude

that this technique is a safe method with a high success rate and a low rate of complications.

Keywords: atrial defect, right heart catheterization, septal occluder, cryptogenic stroke

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karmazín V, Želízko M, Janek B, Marek T, Lupínek P, Brzák M. Percutaneous closure of atrial septal defects. Interv Akut Kardiol. 2016;15(1):37-40. doi: 10.36290/kar.2016.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wagdi P, Ritter M, Salzer F. Prevalence of thrombophilia in patients undergoing closure of patent foramen ovale. Cardiovascular Medicine 2010; 13(4): 111-114. Go to original source...
    2. Bell-Cheddar Y, Amin Z. Indications and Evaluation for ASD Closure. Cardiac Interventions Today SEPTEMBER/OCTOBER 2011: 48-52.
    3. Correspondence. Patent Foramen Ovale and Cryptogenic Stroke. N Engl J Med 369; 1 Nejm.org July 4, 2013: 88-92. Go to original source...
    4. Carroll J, Saver J, et al. Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke. N Engl J Med 368; 12 Nejm. org March 21, 2013: 1092-1100. Go to original source... Go to PubMed...
    5. Furlan A, Jauss M. Patent Foramen Ovale and Cryptogenic StrokeThe Hole Story. Stroke. 2013; 44: 2676-2678. Go to original source... Go to PubMed...
    6. Meier B, Kalesan B, Mattle H, et al. Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism. N Engl J Med 2013; 368: 1083-1091. Go to original source... Go to PubMed...
    7. Dowson A, Mullen M, Peatfield R, et al. Migraine Intervention With STARFlex Technology (MIST) Trial. Circulation. 2008; 117: 1397-1404. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.